J&J says late-stage COVID vaccine trial fully enrolled

 

• Johnson & Johnson (NYSE:JNJ) says it has fully enrolled participants for the first late-stage trial of its COVID-19 single-dose vaccine candidate.
• The Ensemble trial has enrolled ~45K participants and is being conducted by its Janssen unit, J&J says, adding that it expects interim data from the trial by the end of January.
• The company plans to submit an emergency use authorization application to the U.S. Food and Drug Administration in February if the study shows the vaccine is safe and effective.
• The Ensemble trial was paused in October after a patient developed an "unexplained illness" during the study, but J&J resumed the trial after an evaluation found no clear cause for the illness.
• https://seekingalpha.com/news/3645594-j-and-j-says-late-stage-covid-vaccine-trial-fully-enrolled